AIM
BCLI

Acrospire Investment Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Acrospire Investment Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-407
Closed -$25K – 158
2017
Q2 		$25K Buy
407
+168
+70% +$10.4K 0.02% 1392
2017
Q1 		$15K Sell
239
-41
-15% -$2.13K 0.01% 1730
2016
Q4 		$11K Buy
+280
New +$9.71K ﹤0.01% 1925

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Acrospire Investment Management's BCLI Position: Q3 2017 in Review

Acrospire Investment Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2017, closing a stake of 407 shares — an estimated $25K sold.

Acrospire Investment Management first reported a position in BCLI in Q4 2016 and held it in 3 quarters. The position peaked at $25K in Q2 2017. 32 funds tracked by Wall St. Rank hold BCLI as of Q3 2017.

  • Acrospire Investment Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 407 BRAINSTORM CELL THERAPUTC shares in Q3 2017, an estimated $25K.
  • Acrospire Investment Management first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2016 and held it in 3 quarters.
  • Acrospire Investment Management's BRAINSTORM CELL THERAPUTC position peaked at $25K in Q2 2017.
  • 32 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.